Elevance Health (NYSE:ELV) Issues FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) issued an update on its FY 2026 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 27.000- for the period, compared to the consensus estimate of 27.160. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ELV shares. UBS Group boosted their target price on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Raymond James Financial set a $450.00 price target on shares of Elevance Health in a research report on Tuesday, July 7th. Bank of America raised their price target on Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a report on Thursday, June 4th. Wells Fargo & Company dropped their price objective on Elevance Health from $492.00 to $473.00 and set an “overweight” rating on the stock in a research note on Thursday, July 16th. Finally, Barclays reduced their price target on shares of Elevance Health from $480.00 to $457.00 and set an “overweight” rating for the company in a research report on Thursday, July 16th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and an average price target of $440.90.

Elevance Health Price Performance

NYSE ELV opened at $410.71 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68. The company has a market cap of $89.07 billion, a P/E ratio of 18.25, a P/E/G ratio of 2.16 and a beta of 0.69. The company has a fifty day simple moving average of $397.09 and a 200 day simple moving average of $369.87. Elevance Health has a 1 year low of $274.84 and a 1 year high of $436.24.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business had revenue of $49.83 billion for the quarter, compared to the consensus estimate of $48.88 billion. During the same period last year, the business earned $8.84 earnings per share. The firm’s revenue for the quarter was up .8% compared to the same quarter last year. On average, sell-side analysts predict that Elevance Health will post 27.18 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Thursday, September 10th. Elevance Health’s dividend payout ratio (DPR) is currently 30.58%.

About Elevance Health

Elevance Health, Inc is a health benefits and services company that provides health insurance, care management and related healthcare solutions in the United States. The company serves individuals, employers and government-sponsored programs through a portfolio that includes commercial health plans, Medicare Advantage and other Medicare products, Medicaid plans, and specialty coverage.

Elevance Health operates a portfolio of Blue Cross Blue Shield-affiliated health plans and offers products such as medical, pharmacy, dental and vision benefits.